Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V 1.7 inhibitors
Na 1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of Na 1.7. After demonstrating significant pharmacodynamic activity with early lead compound in a Na 1.7-depen...
Gespeichert in:
| Veröffentlicht in: | MedChemComm 2017-04, Vol.8 (4), p.744-754 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 754 |
|---|---|
| container_issue | 4 |
| container_start_page | 744 |
| container_title | MedChemComm |
| container_volume | 8 |
| creator | Sparling, Brian A Yi, S Able, J Bregman, H DiMauro, Erin F Foti, R S Gao, H Guzman-Perez, A Huang, H Jarosh, M Kornecook, T Ligutti, J Milgram, B C Moyer, B D Youngblood, B Yu, V L Weiss, M M |
| description | Na
1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of Na
1.7. After demonstrating significant pharmacodynamic activity with early lead compound
in a Na
1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including Na
1.7 potency, selectivity over Na
1.5, aqueous solubility, and microsomal stability. |
| doi_str_mv | 10.1039/c6md00578k |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1039_C6MD00578K</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30108793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c993-a0b91ab8cce176a30fe5991c538d0763efc6d909ff7a350943a06cb1e9bea6f33</originalsourceid><addsrcrecordid>eNo9kEtPAjEUhRujEYJs_AGma-PgLWUeXRrwFVE3xO3kTnsbKvPKtEyCv14U5WzOWXw5i4-xSwETAVLd6qQyAHGabU7YcAoziKaxEKfHDXLAxt5_wj5ymmVqds4GEgRkqZJDtlk4r5ueuh3H2vC1C1FoopLQcOqx3GJwTc0by1vXUodfriaOlTPkOXruqSQdXE833AcMFBlqqTZUB_6G_IOLScpdvXaFC03nL9iZxdLT-K9HbPVwv5o_Rcv3x-f53TLSSskIoVACi0xrEmmCEizFSgkdy8xAmkiyOjEKlLUpyhjUTCIkuhCkCsLESjli14db3TXed2TztnMVdrtcQP7jLJ8nr4tfZy97-OoAt9uiInNE_w3Jb8sFZ54</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V 1.7 inhibitors</title><source>Royal Society Of Chemistry Journals 2008-</source><source>PubMed Central</source><creator>Sparling, Brian A ; Yi, S ; Able, J ; Bregman, H ; DiMauro, Erin F ; Foti, R S ; Gao, H ; Guzman-Perez, A ; Huang, H ; Jarosh, M ; Kornecook, T ; Ligutti, J ; Milgram, B C ; Moyer, B D ; Youngblood, B ; Yu, V L ; Weiss, M M</creator><creatorcontrib>Sparling, Brian A ; Yi, S ; Able, J ; Bregman, H ; DiMauro, Erin F ; Foti, R S ; Gao, H ; Guzman-Perez, A ; Huang, H ; Jarosh, M ; Kornecook, T ; Ligutti, J ; Milgram, B C ; Moyer, B D ; Youngblood, B ; Yu, V L ; Weiss, M M</creatorcontrib><description>Na
1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of Na
1.7. After demonstrating significant pharmacodynamic activity with early lead compound
in a Na
1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including Na
1.7 potency, selectivity over Na
1.5, aqueous solubility, and microsomal stability.</description><identifier>ISSN: 2040-2503</identifier><identifier>EISSN: 2040-2511</identifier><identifier>DOI: 10.1039/c6md00578k</identifier><identifier>PMID: 30108793</identifier><language>eng</language><publisher>England</publisher><ispartof>MedChemComm, 2017-04, Vol.8 (4), p.744-754</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c993-a0b91ab8cce176a30fe5991c538d0763efc6d909ff7a350943a06cb1e9bea6f33</citedby><cites>FETCH-LOGICAL-c993-a0b91ab8cce176a30fe5991c538d0763efc6d909ff7a350943a06cb1e9bea6f33</cites><orcidid>0000-0001-5184-0956</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30108793$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sparling, Brian A</creatorcontrib><creatorcontrib>Yi, S</creatorcontrib><creatorcontrib>Able, J</creatorcontrib><creatorcontrib>Bregman, H</creatorcontrib><creatorcontrib>DiMauro, Erin F</creatorcontrib><creatorcontrib>Foti, R S</creatorcontrib><creatorcontrib>Gao, H</creatorcontrib><creatorcontrib>Guzman-Perez, A</creatorcontrib><creatorcontrib>Huang, H</creatorcontrib><creatorcontrib>Jarosh, M</creatorcontrib><creatorcontrib>Kornecook, T</creatorcontrib><creatorcontrib>Ligutti, J</creatorcontrib><creatorcontrib>Milgram, B C</creatorcontrib><creatorcontrib>Moyer, B D</creatorcontrib><creatorcontrib>Youngblood, B</creatorcontrib><creatorcontrib>Yu, V L</creatorcontrib><creatorcontrib>Weiss, M M</creatorcontrib><title>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V 1.7 inhibitors</title><title>MedChemComm</title><addtitle>Medchemcomm</addtitle><description>Na
1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of Na
1.7. After demonstrating significant pharmacodynamic activity with early lead compound
in a Na
1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including Na
1.7 potency, selectivity over Na
1.5, aqueous solubility, and microsomal stability.</description><issn>2040-2503</issn><issn>2040-2511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNo9kEtPAjEUhRujEYJs_AGma-PgLWUeXRrwFVE3xO3kTnsbKvPKtEyCv14U5WzOWXw5i4-xSwETAVLd6qQyAHGabU7YcAoziKaxEKfHDXLAxt5_wj5ymmVqds4GEgRkqZJDtlk4r5ueuh3H2vC1C1FoopLQcOqx3GJwTc0by1vXUodfriaOlTPkOXruqSQdXE833AcMFBlqqTZUB_6G_IOLScpdvXaFC03nL9iZxdLT-K9HbPVwv5o_Rcv3x-f53TLSSskIoVACi0xrEmmCEizFSgkdy8xAmkiyOjEKlLUpyhjUTCIkuhCkCsLESjli14db3TXed2TztnMVdrtcQP7jLJ8nr4tfZy97-OoAt9uiInNE_w3Jb8sFZ54</recordid><startdate>20170420</startdate><enddate>20170420</enddate><creator>Sparling, Brian A</creator><creator>Yi, S</creator><creator>Able, J</creator><creator>Bregman, H</creator><creator>DiMauro, Erin F</creator><creator>Foti, R S</creator><creator>Gao, H</creator><creator>Guzman-Perez, A</creator><creator>Huang, H</creator><creator>Jarosh, M</creator><creator>Kornecook, T</creator><creator>Ligutti, J</creator><creator>Milgram, B C</creator><creator>Moyer, B D</creator><creator>Youngblood, B</creator><creator>Yu, V L</creator><creator>Weiss, M M</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-5184-0956</orcidid></search><sort><creationdate>20170420</creationdate><title>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V 1.7 inhibitors</title><author>Sparling, Brian A ; Yi, S ; Able, J ; Bregman, H ; DiMauro, Erin F ; Foti, R S ; Gao, H ; Guzman-Perez, A ; Huang, H ; Jarosh, M ; Kornecook, T ; Ligutti, J ; Milgram, B C ; Moyer, B D ; Youngblood, B ; Yu, V L ; Weiss, M M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c993-a0b91ab8cce176a30fe5991c538d0763efc6d909ff7a350943a06cb1e9bea6f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sparling, Brian A</creatorcontrib><creatorcontrib>Yi, S</creatorcontrib><creatorcontrib>Able, J</creatorcontrib><creatorcontrib>Bregman, H</creatorcontrib><creatorcontrib>DiMauro, Erin F</creatorcontrib><creatorcontrib>Foti, R S</creatorcontrib><creatorcontrib>Gao, H</creatorcontrib><creatorcontrib>Guzman-Perez, A</creatorcontrib><creatorcontrib>Huang, H</creatorcontrib><creatorcontrib>Jarosh, M</creatorcontrib><creatorcontrib>Kornecook, T</creatorcontrib><creatorcontrib>Ligutti, J</creatorcontrib><creatorcontrib>Milgram, B C</creatorcontrib><creatorcontrib>Moyer, B D</creatorcontrib><creatorcontrib>Youngblood, B</creatorcontrib><creatorcontrib>Yu, V L</creatorcontrib><creatorcontrib>Weiss, M M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>MedChemComm</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sparling, Brian A</au><au>Yi, S</au><au>Able, J</au><au>Bregman, H</au><au>DiMauro, Erin F</au><au>Foti, R S</au><au>Gao, H</au><au>Guzman-Perez, A</au><au>Huang, H</au><au>Jarosh, M</au><au>Kornecook, T</au><au>Ligutti, J</au><au>Milgram, B C</au><au>Moyer, B D</au><au>Youngblood, B</au><au>Yu, V L</au><au>Weiss, M M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V 1.7 inhibitors</atitle><jtitle>MedChemComm</jtitle><addtitle>Medchemcomm</addtitle><date>2017-04-20</date><risdate>2017</risdate><volume>8</volume><issue>4</issue><spage>744</spage><epage>754</epage><pages>744-754</pages><issn>2040-2503</issn><eissn>2040-2511</eissn><abstract>Na
1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of Na
1.7. After demonstrating significant pharmacodynamic activity with early lead compound
in a Na
1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including Na
1.7 potency, selectivity over Na
1.5, aqueous solubility, and microsomal stability.</abstract><cop>England</cop><pmid>30108793</pmid><doi>10.1039/c6md00578k</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5184-0956</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2040-2503 |
| ispartof | MedChemComm, 2017-04, Vol.8 (4), p.744-754 |
| issn | 2040-2503 2040-2511 |
| language | eng |
| recordid | cdi_crossref_primary_10_1039_C6MD00578K |
| source | Royal Society Of Chemistry Journals 2008-; PubMed Central |
| title | Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na V 1.7 inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T01%3A32%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20and%20hit-to-lead%20evaluation%20of%20piperazine%20amides%20as%20selective,%20state-dependent%20Na%20V%201.7%20inhibitors&rft.jtitle=MedChemComm&rft.au=Sparling,%20Brian%20A&rft.date=2017-04-20&rft.volume=8&rft.issue=4&rft.spage=744&rft.epage=754&rft.pages=744-754&rft.issn=2040-2503&rft.eissn=2040-2511&rft_id=info:doi/10.1039/c6md00578k&rft_dat=%3Cpubmed_cross%3E30108793%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30108793&rfr_iscdi=true |